P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY

Detalles Bibliográficos
Autores principales: Einsele, H., Dhakal, B., Schecter, J. M., Roccia, T., Deraedt, W., Lendvai, N., Slaughter, A., Lonardi, C., Connors, K., Qi, K., Londhe, A., Carson, R., Voelker, J., Cost, P., Valluri, S., Florendo, E., Pacaud, L., Yong, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Poster
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171564/
http://dx.doi.org/10.1097/01.HS9.0000936268.48048.d9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171564/
http://dx.doi.org/10.1097/01.HS9.0000936268.48048.d9

Ejemplares similares